PT  - JOURNAL ARTICLE
AU  - Schindler, Suzanne E.
AU  - Petersen, Kellen K.
AU  - Saef, Benjamin
AU  - Tosun, Duygu
AU  - Shaw, Leslie M.
AU  - Zetterberg, Henrik
AU  - Dage, Jeffrey L.
AU  - Ferber, Kyle
AU  - Triana-Baltzer, Gallen
AU  - Du-Cuny, Lei
AU  - Li, Yan
AU  - Coomaraswamy, Janaky
AU  - Baratta, Michael
AU  - Mordashova, Yulia
AU  - Saad, Ziad S.
AU  - Raunig, David L.
AU  - Ashton, Nicholas J.
AU  - Meyers, Emily A.
AU  - Rubel, Carrie E.
AU  - Rosenbaugh, Erin G.
AU  - Bannon, Anthony W.
AU  - Potter, William Z.
AU  - ,
AU  - ,
TI  - Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology
AID  - 10.1101/2024.06.12.24308839
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.06.12.24308839
4099  - http://medrxiv.org/content/early/2024/07/03/2024.06.12.24308839.short
4100  - http://medrxiv.org/content/early/2024/07/03/2024.06.12.24308839.full
AB  - Introduction Blood tests have the potential to improve the accuracy of Alzheimer disease (AD) clinical diagnosis, which will enable greater access to AD-specific treatments. This study compared leading commercial blood tests for amyloid pathology and other AD-related outcomes.Methods Plasma samples from the Alzheimer’s Disease Neuroimaging Initiative were assayed with AD blood tests from C2N Diagnostics, Fujirebio Diagnostics, ALZPath, Janssen, Roche Diagnostics, and Quanterix. Outcomes measures were amyloid positron emission tomography (PET), tau PET, cortical thickness, and dementia severity. Logistic regression models assessed the classification accuracies of individual or combined plasma biomarkers for binarized outcomes, and Spearman correlations evaluated continuous relationships between individual plasma biomarkers and continuous outcomes.Results Measures of plasma p-tau217, either individually or in combination with other plasma biomarkers, had the strongest relationships with all AD outcomes.Discussion This study identified the plasma biomarker analytes and assays that most accurately classified amyloid pathology and other AD-related outcomes.Competing Interest StatementS.E.S. has served on advisory boards and received speaking fees from Eisai and Eli Lilly. She has analyzed data from C2N Diagnostics that was provided to Washington University at no cost. S.E. Schindler has not directly received any research or personal compensation from C2N Diagnostics or any other diagnostics companies. K.K.P., B.S., D.T., and E.G.R. have nothing to disclose. L.M.S. receives funding from the NIA for ADNI4 and from NIA for the University of Pennsylvania ADRC P30 for the Biomarker Core. H.Z. has served on scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). J.L.D. is an inventor on patents or patent applications of Eli Lilly and Company relating to the assays, methods, reagents and / or compositions of matter for P-tau assays and Aβ targeting therapeutics. J.L.D. has served as a consultant or on advisory boards for Eisai, Abbvie, Genotix Biotechnologies Inc, Gates Ventures, Karuna Therapeutics, AlzPath Inc., Cognito Therapeutics, Inc., and received research support from ADx Neurosciences, Fujirebio, AlzPath Inc., Roche Diagnostics and Eli Lilly and Company in the past two years. J.L.D. has received speaker fees from Eli Lilly and Company. J.L.D. is a founder and advisor for Monument Biosciences. J.L.D. has stock or stock options in Eli Lilly and Company, Genotix Biotechnologies, AlzPath Inc. and Monument Biosciences. K.F. and C.E.R. are employees of and may own stock in Biogen. G.T.B. and Z.S. are employed by Johnson & Johnson Innovative Medicine and may receive salary and stock for their employment. L.D.C. and Y.M. are employed by AbbVie Deutschland GmbH & Co. Y.L. is the co-inventor of the technology Novel Tau isoforms to predict onset of symptoms and dementia in Alzheimers disease which is in the process of licensing by C2N. J.C., M.B., and D.L.R. receive salary and company stock as compensation for their employment with Takeda Pharmaceutical Company Limited. N.J.A has received speaking fees from Eli Lilly, Biogen, Quanterix and Alamar Biosciences. E.A.M. is employed by the Alzheimers Association. A.W.B. receives salary and company stock as compensation for his employment with AbbVie Inc. W.Z.P. was previously employed by the National Institute of Mental Health, and he is a stockholder in Merck & Co., Inc. He is a Co-Chair Emeritus for the FNIH Biomarkers Consortium Neuroscience Steering Committee. Currently residing in Philadelphia, PA, he serves as a consultant for Karuna, Neurocrine, Neumarker, Vaaji and receives grant support from the NIA along with stock options from Praxis Bioresearch.Funding StatementThe Biomarkers Consortium, Plasma Abeta and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimers Disease Project was made possible through a public-private partnership managed by the Foundation for the National Institute of Health (FNIH) and funded by AbbVie Inc., Alzheimers Association, Diagnostics Accelerator at the Alzheimers Drug Discovery Foundation, Biogen, Janssen Research & Development, LLC, and Takeda Pharmaceutical Company Limited. Statistical analyses were supported in part by National Institute on Aging grant R01AG070941 (S.E.S.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The analyses utilized data from the ADNI database (adni.loni.usc.edu), which studies memory and aging in older adults, including both cognitively unimpaired and cognitively impaired individuals. Written informed consent was obtained from each participant or their legally authorized representative. Race and sex were self-identified. ADNI Study Documents: https://adni.loni.usc.edu/methods/documents/ ADNI governance: https://adni.loni.usc.edu/about/#gov-containerI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData used in the preparation of this article may be obtained from the Alzheimers Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu) https://adni.loni.usc.edu/